Abbvie 1Q Revenues: $12.2 billion (-10%) 1Q Earnings: $241 million (earnings were $4.5 billion in 1Q22) Comments: Revenues from the Immunology Portfolio were $5.6 billion, down 9%. Global Humira sales were $3.5 billion in the quarter, down 25%. Global Skyrizi sales were $1.4 billion, up 45%. Global Rinvoq sales were $686 million, up 48%. Revenues from the Hematologic Oncology Portfolio were $1.4 billion, down 14%, with Imbruvica revenues of $878 million, down 25%, and Venclexta sales of $538 ...